KOROTT

What KOROTT does

KOROTT S.L.U. is a Spanish pharmaceutical-grade CDMO (Contract Development and Manufacturing Organization) headquartered in Alcoy (Alicante), founded in 1991 by two pharmacists and a physician. The company specializes in the formulation, microencapsulation, and manufacturing of probiotic-based dietary supplements and nutraceuticals, operating from an 18,100 m² site with 10,000 m² of certified production space (IFS, BRCGS, GMP, Halal, ISO 14001). Its technical platform supports stability of at least 24 months in climatic zone II and 48 months at ambient conditions without refrigeration, with 100% probiotic viability retained across shelf life, and is supported by two granted patents (WO2018015388 for atopic dermatitis, WO2017162683 for psoriasis) backed by published clinical studies.

The business operates a B2B model serving third-party brand owners, private-label clients, and pharmaceutical laboratories through four interconnected service modules branded as Korott 360º, Korott LAB, Korott Manufacturing, and Korott Marketing. A Ready-to-Market portfolio of six pre-formulated SKUs (PROBIWOMAN, PROBIDIGEST, PROBIMOOD, PROBIDERM, PROBIMETABOLISM, PROBIDEFENCE) enables faster client commercialization, while custom formulation, regulatory registration, stability testing, and analytical services are monetized as professional services. Since June 2021, KOROTT has been a subsidiary of the Hamburg-based EVP Group alongside Euro Vital Pharma (Germany/Slovakia) and Principal Healthcare Group (UK), exporting to 40 countries across Europe, Asia, the Middle East, and Africa.

The company is privately held and does not disclose revenue, pricing, or unit economics publicly; all commercial engagement is routed through direct inquiry. With approximately 145 employees at the Alcoy facility (49% with specialized training, 79% permanent, 34% with tenure over 10 years), KOROTT positions itself as a specialized European CDMO for scientifically validated probiotic and nutraceutical white-label manufacturing.

Name

KOROTT

Legal name

KOROTT S.L.U.

Website

https://korott.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

101–250 employees

Short description

KOROTT is a Spanish pharmaceutical-grade CDMO founded in 1991 that formulates, microencapsulates, and manufactures probiotic dietary supplements and nutraceuticals for third-party brands, private-label clients, and pharmaceutical laboratories across 40 countries, and has been a subsidiary of Hamburg-based EVP Group since June 2021.

Ownership category

akta.pro rank

Headquarters

HQ city

Alicante

HQ country

Spain

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. CDMO Manufacturing Services (Third-Party & White-Label): KOROTT develops and manufactures dietary supplements and nutraceuticals for third-party brands and white-label customers under its CDMO model. The company handles the full product lifecycle from concept and formulation through manufacturing and regulatory compliance. Revenue is generated through manufacturing fees and product development charges billed to B2B clients.
2. Custom Formulation and R&D Services: The company's Korott LAB division provides customized probiotic formulations based on client-specific requirements, with scientific and clinical backing. Fees are charged for formulation development, regulatory registration, stability testing, and analytical services.
3. Ready-to-Market (RTM) Product Portfolio: KOROTT offers a catalog of pre-formulated probiotic products (PROBIWOMAN, PROBIDIGEST, PROBIMOOD, PROBIDERM, PROBIMETABOLISM, PROBIDEFENCE) ready for clients to brand and commercialize, enabling faster market entry and revenue generation without custom development timelines.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

KOROTT is a B2B contract development and manufacturing organization (CDMO) that develops and produces probiotic and nutraceutical products on behalf of third-party brand owners. Its offering spans formulation R&D (Korott LAB), production and packaging (Korott Manufacturing), regulatory and marketing support (Korott Marketing), and a Ready-to-Market (RTM) portfolio of probiotic SKUs that clients can take over as their own brands. Headquartered in Alcoy (Alicante), Spain, the company has operated since June 2021 as a subsidiary of the Hamburg-based EVP Group.

Product overview

KOROTT is a B2B laboratory specializing in probiotic and nutraceutical product development and manufacturing. The company offers an integrated CDMO (Contract Development and Manufacturing Organization) service model through four interconnected modules: Korott® 360º (comprehensive service from idea to finished product), Korott® LAB (custom formulation and R&D), Korott® Manufacturing (production), and Korott® Marketing (commercial support). The core product portfolio consists of six Ready-to-Market probiotic formulations (PROBIWOMAN, PROBIDIGEST, PROBIMOOD, PROBIDERM, PROBIMETABOLISM, PROBIDEFENCE) targeting different therapeutic areas including urogenital, digestive, emotional, dermatological, metabolic, and immune health. Manufacturing capabilities support multiple packaging formats including doy packs, sticks, vials (10ml and 25ml), boxes with blisters, capsule containers, powder sachets, and powder cans.

Differentiator

Problem solved

Functional benefit

Products and services

• ProbiWoman Ready-to-Market (RTM) probiotic formulation positioned for women's health, designed to be taken over and sold under third-party brand owners' labels.
• ProbiDigest Ready-to-Market probiotic formulation positioned for digestive/gut health, designed to be taken over and sold under third-party brand owners' labels.
• ProbiMood Ready-to-Market probiotic formulation positioned for mood and emotional wellbeing, designed to be taken over and sold under third-party brand owners' labels.
• ProbiDerm Ready-to-Market probiotic formulation positioned for skin health, designed to be taken over and sold under third-party brand owners' labels.
• ProbiMetabolism Ready-to-Market probiotic formulation positioned for metabolic support, designed to be taken over and sold under third-party brand owners' labels.
• ProbiDefence Ready-to-Market probiotic formulation positioned for immune defence, designed to be taken over and sold under third-party brand owners' labels.
• Korott LAB Contract research and development service for probiotics and nutraceuticals, supporting client projects from early concept through to validated formulation, using capabilities including KORBIOTICS microencapsulation and REPROBIOMA metagenomic study.
• Korott Manufacturing Contract manufacturing service producing probiotic and nutraceutical finished products at the 18,100 m² Alcoy facility, supporting around 300 SKUs across multiple packaging formats and shipping into around 40 countries.
• Korott Marketing Marketing and brand support service assisting third-party clients in launching probiotic and nutraceutical products to market.
• Korott 360° End-to-end CDMO service umbrella integrating Korott LAB, Korott Manufacturing, and Korott Marketing into a single contracted offering for third-party brand owners.

Quantifiable outcome

• Atopic dermatitis: 83% improvement in probiotic group vs 24% in placebo group (SCORAD index) — published in JAMA Dermatology 2018, 154(1), 37-43. Patent WO2018015388.
• +4 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

• EVP Group (Hamburg, Germany)flagshipStrategic or Co-development Partner · 1 June 2021In June 2021, KOROTT became part of the EVP Group based in Hamburg, Germany, joining Euro Vital Pharma and Principal Healthcare Group. EVP Group is a pan-European CDMO and white-label provider for consumer healthcare, serving retailers, wholesalers, pharmacies, and companies across Europe and globally. KOROTT serves as the Spanish manufacturing hub within the group, contributing probiotic formulation expertise and Southern European market access.
• Euro Vital Pharma (Germany/Slovakia)coreStrategic or Co-development PartnerEuro Vital Pharma, based in Germany with production in Dunajská Streda, Slovakia (~140 employees, 6,000 m² facilities), is a sister company within the EVP Group. It specializes in tablets, chewables, and effervescent products, complementing KOROTT's probiotic and capsule manufacturing capabilities. The companies collaborate on cross-selling and serving the European private-label supplements market.
• Principal Healthcare Group (UK)coreStrategic or Co-development PartnerPrincipal Healthcare Group, based in Skipton, UK (~20 employees), is a sister company within the EVP Group and a leader in the UK private-label food supplements market. It collaborates with KOROTT to serve the UK market and expand the group's European footprint in health supplements.
• Acceseo Projects SlminorOthersAcceseo Projects Sl (CIF: B42621300, Calle Oliver 21, Alcoy, 03802, Alicante) is a data processing partner with whom KOROTT shares personal data for specific operational activities, as disclosed in the company's privacy policy.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Recipharm: Large European pharmaceutical CDMO offering development and manufacturing services across solid, semi-solid, and sterile dosage forms. Overlaps with KOROTT's CDMO positioning for pharma-grade nutraceuticals but at much greater scale and breadth.
• ADM Nutrition: Global nutrition and ingredient giant with a health and wellness division supplying probiotics, prebiotics, and postbiotics to supplement brands. Comparable as a B2B probiotic supplier to white-label customers, but at vastly greater scale and portfolio breadth.
• Catalent: Global pharmaceutical CDMO offering formulation, clinical and commercial manufacturing across multiple dosage forms including softgels and oral solids. Overlaps with KOROTT's CDMO model but operates at much larger scale and across multiple therapeutic categories.
• Lallemand Health Solutions: Probiotic and yeast manufacturer supplying documented strains for human nutrition and pharma applications. Overlaps with KOROTT on documented probiotic strain supply to B2B brand customers in the nutraceutical channel.
• Novonesis (formerly Chr. Hansen): Global microbial and fermentation powerhouse combining Chr. Hansen's probiotic cultures with Novozymes' enzymes. Comparable as a clinically-documented probiotic ingredient supplier and increasingly a formulation partner, though vastly larger and broader.
• Aenova Group: European CDMO leader in solid dosage forms, softgels, and sterile liquids serving pharma and consumer health customers. Comparable as a pan-European CDMO serving nutraceutical and OTC customers, though broader in portfolio than KOROTT's probiotic specialization.
• Kerry Group (GanedenBC30): Global taste and nutrition platform that acquired Ganeden, a branded probiotic ingredient supplier to food, beverage, and supplement customers. Comparable in supplying clinically-supported probiotic ingredients to B2B brand owners, but at much greater scale.
• Lesaffre: Global yeast and fermentation group with a human care division offering probiotic ingredients and finished formulations. Comparable as a fermentation-based probiotic supplier serving nutraceutical brands, with broader food and baking exposure.

Direct peers

• BioGaia: Swedish probiotic specialist that develops, documents clinically, and licenses Lactobacillus reuteri strains for B2B brand customers in gut, oral, and infant health. Directly comparable therapeutic-area, clinical-evidence, and licensing-led business model.
• Probi AB: Swedish probiotic R&D and CDMO player offering clinically-documented probiotic strains and contract manufacturing to brand owners across Europe, the US, and Asia. Closest direct comparable by size, B2B probiotic focus, and clinical-evidence-led positioning.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/korott

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KOROTT